Protagenic Therapeutics, Inc. (NASDAQ:PTIX) Short Interest Update

Protagenic Therapeutics, Inc. (NASDAQ:PTIX) was the recipient of a significant increase in short interest in the month of January. As of January 15th, there was short interest totalling 175,300 shares, an increase of 255.6% from the December 31st total of 49,300 shares. Based on an average trading volume of 272,300 shares, the days-to-cover ratio is currently 0.6 days. Currently, 2.8% of the shares of the company are sold short.

Protagenic Therapeutics Price Performance

Shares of NASDAQ PTIX opened at $0.47 on Wednesday. Protagenic Therapeutics has a 12-month low of $0.40 and a 12-month high of $1.87. The stock’s 50 day simple moving average is $0.53 and its 200 day simple moving average is $0.61.

About Protagenic Therapeutics

Protagenic Therapeutics, Inc, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses.